United States

BioCryst Pharmaceuticals to merge with Presidio Pharmaceuticals

Friday, October 19, 2012 11:34 AM

BioCryst Pharmaceuticals, a Durham, N.C.-based and developer of novel small molecule drugs that block key enzymes involved in infectious and inflammatory diseases, and Presidio Pharmaceuticals, a San Francisco-based clinical stage specialty pharmaceutical company, have signed a definitive merger agreement for Presidio to be acquired by BioCryst in an all-stock transaction.

More... »

FDA approves Jetrea for symptomatic VMA in eyes

Wednesday, October 17, 2012 02:47 PM

The FDA has approved ThromboGenics’ Jetrea (ocriplasmin), the first drug approved to treat an eye condition called symptomatic vitreomacular adhesion (VMA).

More... »

Clinical research sites honor Eli Lilly, Medpace with Eagle Awards

Monday, October 15, 2012 11:57 AM

The 2012 Eagle Awards, presented to the top sponsor and top CRO as voted by clinical research sites, honored Eli Lilly and Medpace on Saturday, Oct. 13, at the annual Site Solutions Summit.

More... »

Fate Therapeutics names Christian Weyer president, CEO

Monday, October 15, 2012 11:44 AM

San Diego, Calif.-based Fate Therapeutics has appointed Christian Weyer, M.D., M.A.S., president and CEO, and elected him to the board of directors, effective immediately.

More... »

Arena initiates phase I trial of APD811 for hypertension

Friday, October 12, 2012 02:46 PM

Arena Pharmaceuticals, a San Diego-based biopharmaceutical company focused on novel drugs for weight management, cardiovascular disease, inflammation and other disorders, has initiated dosing in a phase I multiple dose clinical trial of APD811, a novel oral drug candidate discovered by Arena that targets the prostacyclin (IP) receptor for the treatment of pulmonary arterial hypertension (PAH).

More... »

StemCells announces first transplant of neural stem cells into patient with dry AMD

Thursday, October 11, 2012 07:00 AM

StemCells, a cell-based therapeutics company of Newark, Calif., has enrolled and transplanted stem cells into the first patient in its phase I/II clinical trial in dry age-related macular degeneration (AMD).

More... »

Amarantus, RBCC target NuroPro Parkinson's diagnostic for joint venture

Wednesday, October 10, 2012 11:03 AM

Amarantus BioSciences, a Sunnyvale, Calif.-based biotech focused on brain-related disorders including Parkinson's disease and traumatic brain injury (TBI), and Rainbow Coral (RBCC), a biotech subsidiary Rainbow BioSciences, have selected NuroPro, Amarantus' Parkinson's disease blood test in development, as the target product candidate for the proposed joint venture.

More... »

Survey: U.S. adults trust Internet more than pharmacist on health care decisions

Wednesday, October 10, 2012 09:51 AM

A new RxAlly survey revealed that only 18% of U.S. adults trust a pharmacist most to help guide and inform healthcare decisions for themselves and their families. A majority of people trust their doctor most 72%, followed by friends and family 36%, spouses or significant others 36% and the Internet 22%.

More... »

Theorem optimizes services for regulatory and clinical issues

Wednesday, October 10, 2012 09:22 AM

Theorem Clinical Research, a King of Prussia, Penn.-based full-service CRO that provides core clinical R&D services, also helps clients identify and strategically address early and ongoing device-related regulatory and clinical issues.

More... »

Life Technologies acquires Compendia Bioscience

Tuesday, October 9, 2012 02:54 PM

Carlsbad, Calif.-based Life Technologies is acquiring Compendia Bioscience, a cancer bioinformatics company helping the pharmaceutical industry to identify novel gene targets for drug discovery and development.

More... »